$12 million seed funding round led by Oxford Science Enterprises and Apollo Health Ventures, with AlbionVC, YZR Capital, and Parkwalk Advisors, and support from Oxford University Innovation Scripta ...

CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial ...

FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class ...

As states cut Medicaid coverage for GLP-1 drugs, access to obesity treatment is increasingly tied to income—raising questions for both Medicaid and Medicare.

How innovative technologies like AI and gene editing are advancing rare disease drug discovery and development.

Scripta’s unique approach is based on the concept that transcription factors, the master controllers of gene expression, are core drivers of disease and act as detailed and dynamic maps of the ...